atorvastatin has been researched along with Lung Neoplasms in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 16 (69.57) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Al Dujaily, E; Alhamad, S; Giblett, S; Kamata, T; Le Quesne, J; Margaritaki, O; Pringle, JH; Pritchard, C; So, TY | 1 |
| Tulbah, AS | 1 |
| Cao, YJ; Gu, SM; Lei, QQ; Li, LY; Li, XJ; Li, YQ; Pan, Y; Tie, L; Wang, YR; Xiang, LY; Yang, X | 1 |
| Ali, A; Chen, L; Chin, TM; Clohessy, JG; Fhu, CW; Goggi, JL; Levantini, E; Tenen, DG; Teo, JT; Wu, CS | 1 |
| Cheng, X; Gan, X; He, S; Huang, Y; Li, S; Li, Z; Yang, N; Zhang, L; Zheng, F | 1 |
| Arand, J; Byers, LA; Cam, LL; Cao, S; Coles, GL; Contrepois, K; Cristea, S; Drainas, AP; Gershkovitz, M; He, A; Hornburg, D; Kim, JW; Sage, J; Sen, T; Snyder, MP; Williamson, SC | 1 |
| Aksoy, HN; Ceylan, C | 1 |
| Aouba, A | 1 |
| Beckwitt, CH; Clark, AM; Ma, B; Oltvai, ZN; Wells, A; Whaley, D | 1 |
| Hou, T; Lee, SM; Li, P; Li, S; Li, Y; Pan, P; Shen, M; Yu, H; Zhang, L; Zhou, S | 1 |
| Bi, H; Chen, J; Hou, J; Liu, B; Liu, D; Liu, J; Shi, H; Wen, X; Yuan, J; Yue, L; Zhang, C; Zhang, X | 1 |
| Chen, X; Li, Y; Meng, Q; Sun, H; Xu, P; Yin, Q; Yu, H; Zhang, Z | 1 |
| Alfonso, H; Lake, RA; Musk, AW; Nowak, AK; Olsen, N; Robinson, BW; Robinson, C; Walsh, A; Woo, S | 1 |
| Ishak, RA; Osman, R | 1 |
| Fan, Z; Jiang, H; Qu, J; Wang, Z | 1 |
| Jin, H; Lin, Y; Lu, G; Snagaski, B; Xiao, H; Yang, CS; You, H | 1 |
| Barbry, P; Fromigue, O; Hamidouche, Z; Lecanda, F; Mari, B; Marie, PJ; Patino, A; Vaudin, P | 1 |
| Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P | 1 |
| An, Y; Chen, J; Li, X; Liu, B; Pan, Y; Tie, L; Yang, J; Yuan, J; Zhang, J | 1 |
| Casto, BC; Knobloch, TJ; Lubet, RA; Pereira, MA; Steele, VE; Warner, BM; Weghorst, CM | 1 |
| An, Y; Chen, J; Hou, J; Lan, T; Li, X; Liu, J; Pan, Y; Tie, L; Zhang, J | 1 |
| An, Y; Chen, J; Hou, J; Li, X; Liu, J; Yue, L; Zhang, J; Zhang, X | 1 |
| Ewy, GA | 1 |
1 trial(s) available for atorvastatin and Lung Neoplasms
| Article | Year |
|---|---|
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome | 2012 |
22 other study(ies) available for atorvastatin and Lung Neoplasms
| Article | Year |
|---|---|
Statins mediate anti- and pro-tumourigenic functions by remodelling the tumour microenvironment.
Topics: Adenocarcinoma of Lung; Animals; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Mice; Tumor Microenvironment | 2022 |
Inhaled Atorvastatin Nanoparticles for Lung Cancer.
Topics: Administration, Inhalation; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Nanoparticles; Particle Size; Respiratory Aerosols and Droplets | 2022 |
Prediction and validation of common targets in atherosclerosis and non-small cell lung cancer influenced by atorvastatin.
Topics: Atorvastatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Matrix Metalloproteinase 12; Matrix Metalloproteinase 9 | 2023 |
CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Caveolin 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Energy Metabolism; ErbB Receptors; Female; Glucose; Glucose Transporter Type 3; Humans; Lung; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Mutation; Signal Transduction | 2019 |
The Pharmacogenomics "Side-effect" of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis.
Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Databases, Chemical; Databases, Genetic; ErbB Receptors; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Protein Interaction Maps; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2019 |
The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.
Topics: Animals; Atorvastatin; Cell Line, Tumor; Cell Survival; Cholesterol; Gene Knockdown Techniques; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipidomics; Lung Neoplasms; MAP Kinase Kinase 5; MAP Kinase Signaling System; Mevalonic Acid; Mice; Mitogen-Activated Protein Kinase 7; RNA-Seq; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2020 |
Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
Topics: A549 Cells; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Lung Neoplasms; Pravastatin; Rosuvastatin Calcium; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2021 |
KRAS
Topics: Atorvastatin; Humans; Lung Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2017 |
Statins attenuate outgrowth of breast cancer metastases.
Topics: Animals; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Epithelial-Mesenchymal Transition; Female; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lung Neoplasms; MCF-7 Cells; Mice; Xenograft Model Antitumor Assays | 2018 |
Discovery of Rho-kinase inhibitors by docking-based virtual screening.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cerebral Hemorrhage; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; HeLa Cells; Heptanoic Acids; Humans; Lung Neoplasms; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Multiple Myeloma; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases; Zebrafish | 2013 |
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Quinazolines; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis.
Topics: Animals; Atorvastatin; Breast; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Female; Heptanoic Acids; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Neoplasms; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Oxidation-Reduction; Polyethylene Glycols; Pyrroles; Vitamin E | 2014 |
Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asbestos; Atorvastatin; Cohort Studies; Cyclooxygenase 2 Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lung Neoplasms; Male; Mesothelioma; Mice; Mice, Transgenic; Middle Aged; Pyrroles | 2014 |
Lecithin/TPGS-based spray-dried self-microemulsifying drug delivery systems: In vitro pulmonary deposition and cytotoxicity.
Topics: Administration, Inhalation; Aerosols; Atorvastatin; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Desiccation; Dose-Response Relationship, Drug; Drug Carriers; Drug Stability; Emulsions; Humans; Inhibitory Concentration 50; Lecithins; Lung; Lung Neoplasms; Particle Size; Polyethylene Glycols; Powders; Solubility; Surface-Active Agents; Technology, Pharmaceutical; Vitamin E | 2015 |
Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-β1 by attenuating the upregulation of SphK1.
Topics: A549 Cells; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Signal Transduction; Transcription, Genetic; Transcriptional Activation; Transforming Growth Factor beta1; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin.
Topics: Animals; Apoptosis; Atorvastatin; Catechin; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Flavonoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Mice; Phenols; Plant Extracts; Polyphenols; Pyrroles; Tea | 2008 |
CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis.
Topics: Animals; Apoptosis; Atorvastatin; Bone and Bones; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Cysteine-Rich Protein 61; Down-Regulation; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Osteosarcoma; Prenylation; Pyrroles | 2011 |
Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production.
Topics: Animals; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Catalase; Cell Line, Tumor; Cell Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Nude; NADPH Oxidases; Protein Transport; Pyrroles; rac1 GTP-Binding Protein; Reactive Oxygen Species; Vascular Endothelial Growth Factor A | 2012 |
Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.
Topics: Animals; Atorvastatin; Colonic Neoplasms; Dimethylhydrazines; Female; Heptanoic Acids; Histone Deacetylase Inhibitors; Hydroxamic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Mice; Nitrosamines; Pyrroles; RNA, Messenger; Urethane; Vorinostat | 2012 |
Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Xenograft Model Antitumor Assays | 2012 |
Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Interferon-gamma; Lung Neoplasms; Mice; Organ Specificity; Pyrroles; rhoA GTP-Binding Protein | 2012 |
Antioxidant therapy for coronary artery disease: don't paint the walls without treating the termites!
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Lung Neoplasms; Oxidation-Reduction; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Treatment Outcome; Vitamin A; Vitamin E | 1999 |